
Tucatinib authorised by UK’s MHRA for locally advanced or metastatic HER2-positive breast cancer
Seagen UK Ltd. today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA)…
Seagen UK Ltd. today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA)…
Final analysis of results from a randomised clinical trial of lapatinib and trastuzumab given before…
The Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and…
The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol…
Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the…
Statins are widely used to lower cholesterol and prevent heart disease and related deaths, but…
Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such…
Data from six-year analysis of the APHINITY trial showed that adding pertuzumab to the previous…
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with…
More and more patients are being treated successfully for cancer. However, some cancer treatments that…